ArticleJournal of the American Society of Nephrology : JASN2025
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2026Pooled it
- Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026Pooled it
- Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.Journal of the American Society of Nephrology : JASN · 2026Trial
- IgA nephropathy management: what does the future hold?Kidney international supplements · 2026Review
- Tonsillar Tfh cells contribute to the pathogenesis of IgA nephropathy in collaboration with memory B cells.Frontiers in immunology · 2026Article
- Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis.Renal failure · 2025Article
- Review
- IgA Nephropathy: An Overview of the Clinical Trials.Kidney medicine · 2025Review
- Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease-A practical update for clinicians.Diabetes, obesity & metabolism · 2025Review
- Review
- Treating IgA Nephropathy: Looking at the Future Without Forgetting the Past.Journal of clinical medicine · 2025Review
- Authors' Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?Journal of the American Society of Nephrology : JASN · 2025Article
- Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?Journal of the American Society of Nephrology : JASN · 2025Article
- From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2025Article
- Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis.Clinical kidney journal · 2025Article
- The road ahead: emerging therapies for primary IgA nephropathy.Frontiers in nephrology · 2025Review
- Opportunities and challenges in the treatment of IgA nephropathy.Frontiers in pharmacology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.